

# Lia D'Ambrosio

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5746088/publications.pdf>

Version: 2024-02-01

81  
papers

6,029  
citations

66315

42  
h-index

71651

76  
g-index

82  
all docs

82  
docs citations

82  
times ranked

4577  
citing authors

#	ARTICLE	IF	CITATIONS
1	Towards tuberculosis elimination: an action framework for low-incidence countries. <i>European Respiratory Journal</i> , 2015, 45, 928-952.	3.1	608
2	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. <i>Lancet, The</i> , 2018, 392, 821-834.	6.3	452
3	Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. <i>European Respiratory Journal</i> , 2012, 40, 1430-1442.	3.1	346
4	Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. <i>European Respiratory Journal</i> , 2013, 42, 156-168.	3.1	346
5	Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. <i>European Respiratory Journal</i> , 2020, 56, 2001398.	3.1	273
6	Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. <i>European Respiratory Journal</i> , 2017, 49, 1700387.	3.1	233
7	Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. <i>European Respiratory Journal</i> , 2013, 42, 169-179.	3.1	226
8	Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. <i>European Respiratory Journal</i> , 2013, 42, 252-271.	3.1	211
9	Tuberculosis elimination: theory and practice in Europe. <i>European Respiratory Journal</i> , 2014, 43, 1410-1420.	3.1	148
10	Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. <i>European Respiratory Journal</i> , 2016, 47, 394-402.	3.1	136
11	Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January–April 2020. <i>Emerging Infectious Diseases</i> , 2020, 26, 2709-2712.	2.0	133
12	MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. <i>International Journal of Infectious Diseases</i> , 2020, 92, S15-S25.	1.5	126
13	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. <i>European Respiratory Journal</i> , 2019, 54, 1901522.	3.1	113
14	Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. <i>European Respiratory Journal</i> , 2017, 50, 1701462.	3.1	103
15	ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. <i>European Respiratory Journal</i> , 2014, 44, 811-815.	3.1	96
16	Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. <i>European Respiratory Journal</i> , 2016, 47, 1235-1243.	3.1	92
17	Epidemic and pandemic viral infections: impact on tuberculosis and the lung. <i>European Respiratory Journal</i> , 2020, 56, 2001727.	3.1	89
18	Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study. <i>European Respiratory Journal</i> , 2021, 58, 2101786.	3.1	86

#	ARTICLE	IF	CITATIONS
19	First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline. <i>European Respiratory Journal</i> , 2016, 48, 935-938.	3.1	84
20	Classifying new anti-tuberculosis drugs: rationale and future perspectives. <i>International Journal of Infectious Diseases</i> , 2017, 56, 181-184.	1.5	82
21	Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe. <i>European Respiratory Journal</i> , 2019, 53, 1900391.	3.1	81
22	Tuberculosis elimination: where are we now?. <i>European Respiratory Review</i> , 2018, 27, 180035.	3.0	76
23	Tuberculosis care among refugees arriving in Europe: a ERS/WHO Europe Region survey of current practices. <i>European Respiratory Journal</i> , 2016, 48, 808-817.	3.1	75
24	Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines. <i>Clinical Infectious Diseases</i> , 2015, 61, S102-S118.	2.9	74
25	Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges. <i>European Respiratory Journal</i> , 2016, 48, 938-943.	3.1	71
26	Comparison of effectiveness and safety of imipenem/clavulanate-versusmeropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. <i>European Respiratory Journal</i> , 2016, 47, 1758-1766.	3.1	69
27	Faster for less: the new "shorter" regimen for multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2016, 48, 1503-1507.	3.1	66
28	Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience. <i>European Respiratory Journal</i> , 2016, 47, 333-336.	3.1	64
29	Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil. <i>European Respiratory Journal</i> , 2017, 49, 1602445.	3.1	63
30	Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline. <i>European Respiratory Journal</i> , 2017, 49, 1700146.	3.1	59
31	Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review. <i>European Respiratory Journal</i> , 2018, 52, 1800934.	3.1	59
32	The definition of tuberculosis infection based on the spectrum of tuberculosis disease. <i>Breathe</i> , 2021, 17, 210079.	0.6	59
33	Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. <i>European Respiratory Journal</i> , 2014, 43, 289-292.	3.1	54
34	Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review. <i>Journal of Thoracic Disease</i> , 2017, 9, 2093-2101.	0.6	52
35	Pulmonary rehabilitation is effective in patients with tuberculosis pulmonary sequelae. <i>European Respiratory Journal</i> , 2019, 53, 1802184.	3.1	51
36	ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update. <i>European Respiratory Journal</i> , 2018, 51, 1702678.	3.1	50

#	ARTICLE	IF	CITATIONS
37	WHO recommendations on shorter treatment of multidrug-resistant tuberculosis. <i>Lancet, The</i> , 2016, 387, 2486-2487.	6.3	47
38	Tuberculosis elimination: dream or reality? The case of Cyprus. <i>European Respiratory Journal</i> , 2014, 44, 543-546.	3.1	46
39	Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence: Table 1. <i>European Respiratory Journal</i> , 2013, 42, 288-290.	3.1	45
40	Surgery and pleuro-pulmonary tuberculosis: a scientific literature review. <i>Journal of Thoracic Disease</i> , 2016, 8, E474-E485.	0.6	45
41	Is there a rationale for pulmonary rehabilitation following successful chemotherapy for tuberculosis?. <i>Jornal Brasileiro De Pneumologia</i> , 2016, 42, 374-385.	0.4	45
42	Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis. <i>Emerging Infectious Diseases</i> , 2017, 23, 1718-1721.	2.0	43
43	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study. <i>International Journal of Infectious Diseases</i> , 2019, 83, 72-76.	1.5	41
44	Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives. <i>Journal of Thoracic Disease</i> , 2016, 8, 2666-2671.	0.6	39
45	Drug resistant TB – latest developments in epidemiology, diagnostics and management. <i>International Journal of Infectious Diseases</i> , 2022, 124, S20-S25.	1.5	37
46	WHO strategies for the programmatic management of drug-resistant tuberculosis. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 991-1002.	1.0	34
47	Call for urgent actions to ensure access to early diagnosis and care of tuberculosis among refugees. <i>European Respiratory Journal</i> , 2016, 47, 1345-1347.	3.1	34
48	Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. <i>Clinical Infectious Diseases</i> , 2016, 62, 1188.2-1190.	2.9	34
49	The European Union standards for tuberculosis care: do they need an update?. <i>European Respiratory Journal</i> , 2014, 43, 933-942.	3.1	30
50	Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery. <i>Journal of Infection</i> , 2019, 78, 35-39.	1.7	30
51	Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. <i>European Respiratory Journal</i> , 2016, 48, 1160-1170.	3.1	27
52	Current use and acceptability of novel diagnostic tests for active tuberculosis: a worldwide survey. <i>Jornal Brasileiro De Pneumologia</i> , 2017, 43, 380-392.	0.4	26
53	Resistance profile of drugs composing the “shorter” regimen for multidrug-resistant tuberculosis in Brazil, 2000–2015. <i>European Respiratory Journal</i> , 2017, 49, 1602309.	3.1	25
54	Diabetes is Associated With Severe Adverse Events in Multidrug-Resistant Tuberculosis. <i>Archivos De Bronconeumologia</i> , 2017, 53, 245-250.	0.4	23

#	ARTICLE	IF	CITATIONS
55	La diabetes se asocia con reacciones adversas graves en la tuberculosis multirresistente. Archivos De Bronconeumologia, 2017, 53, 245-250.	0.4	23
56	Shifting from tuberculosis control to elimination: Where are we? What are the variables and limitations? Is it achievable?. International Journal of Infectious Diseases, 2017, 56, 30-33.	1.5	22
57	Children under 5 years are at risk for tuberculosis after occasional contact with highly contagious patients: outbreak from a smear-positive healthcare worker. European Respiratory Journal, 2017, 50, 1701414.	3.1	21
58	Challenging MDR-TB clinical problems – The case for a new Global TB Consilium supporting the compassionate use of new anti-TB drugs. International Journal of Infectious Diseases, 2019, 80, S68-S72.	1.5	21
59	Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains. European Respiratory Journal, 2015, 45, 287-289.	3.1	19
60	Tuberculosis elimination: a dream or a reality? The case of Oman. European Respiratory Journal, 2018, 51, 1702027.	3.1	18
61	Tuberculosis, COVID-19 and hospital admission: Consensus on pros and cons based on a review of the evidence. Pulmonology, 2021, 27, 248-256.	1.0	18
62	Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis. International Journal of Infectious Diseases, 2022, 124, S90-S103.	1.5	18
63	Cameroon's multidrug-resistant tuberculosis treatment programme jeopardised by cross-border migration. European Respiratory Journal, 2016, 47, 686-688.	3.1	17
64	Coronavirus Disease-19: An Interim Evidence Synthesis of the World Association for Infectious Diseases and Immunological Disorders (Waidid). Frontiers in Medicine, 2020, 7, 572485.	1.2	15
65	Tuberculosis and COVID-19, the new cursed duet: what differs between Brazil and Europe?. Jornal Brasileiro De Pneumologia, 2021, 47, 20210044.	0.4	15
66	Key role of tuberculosis services funding mechanisms in tuberculosis control and elimination. European Respiratory Journal, 2015, 45, 289-291.	3.1	14
67	Diagnostic performances of the Xpert MTB/RIF in Brazil. Respiratory Medicine, 2018, 134, 12-15.	1.3	13
68	Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico. European Respiratory Journal, 2018, 51, 1702267.	3.1	10
69	Country-specific lockdown measures in response to the COVID-19 pandemic and its impact on tuberculosis control: a global study. Jornal Brasileiro De Pneumologia, 2022, 48, e20220087.	0.4	10
70	Recent evidence on delamanid use for rifampicin-resistant tuberculosis. Journal of Thoracic Disease, 2019, 11, S457-S460.	0.6	9
71	History of prevention, diagnosis, treatment and rehabilitation of pulmonary sequelae of tuberculosis. Presse Medicale, 2022, 51, 104112.	0.8	9
72	Post-Tuberculosis (TB) Treatment: The Role of Surgery and Rehabilitation. Applied Sciences (Switzerland), 2020, 10, 2734.	1.3	8

#	ARTICLE	IF	CITATIONS
73	The multidrug-resistant tuberculosis threat: old problems and new solutions. <i>Journal of Thoracic Disease</i> , 2015, 7, E354-60.	0.6	8
74	A new free-cost e-service supporting clinicians to manage their difficult-to-treat TB cases: the ERS-WHO TB consilium. <i>Journal of Thoracic Disease</i> , 2015, 7, 1080-5.	0.6	8
75	Estrategias de la OMS para el tratamiento de la tuberculosis resistente. <i>Archivos De Bronconeumologia</i> , 2017, 53, 95-97.	0.4	6
76	Post-tuberculosis lung disease: a comparison of Brazilian, Italian, and Mexican cohorts. <i>Jornal Brasileiro De Pneumologia</i> , 2022, 48, e20210515.	0.4	6
77	WHO Strategies for the Management of Drug-Resistant Tuberculosis. <i>Archivos De Bronconeumologia</i> , 2017, 53, 95-97.	0.4	5
78	International collaboration among medical societies is an effective way to boost Latin American production of articles on tuberculosis. <i>Jornal Brasileiro De Pneumologia</i> , 2019, 45, e20180420.	0.4	5
79	Screening for Tuberculosis in Migrants: A Survey by the Global Tuberculosis Network. <i>Antibiotics</i> , 2021, 10, 1355.	1.5	5
80	Performance of a lateral flow immunochromatography test for the rapid diagnosis of active tuberculosis in a large multicentre study in areas with different clinical settings and tuberculosis exposure levels. <i>Journal of Thoracic Disease</i> , 2016, 8, 3307-3313.	0.6	3
81	A new free-cost e-service supporting clinicians to manage their difficult-to-treat tuberculosis cases: The European Respiratory Society-World Health Organization tuberculosis Consilium. <i>Indian Journal of Medical Research</i> , 2017, 145, 261-263.	0.4	0